This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synta Announces Appointment Of Sumant Ramachandra, M.D., Ph.D. As President, Research And Development

Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced the appointment of Dr. Sumant Ramachandra as President, Research and Development.

Prior to Synta, Dr. Ramachandra was Senior Vice President, Research and Development (R&D), Regulatory and Medical Affairs, and Chief Scientific Officer of Hospira, a specialty pharmaceuticals and medical device company. At Hospira, Dr. Ramachandra led a 1,200 person R&D organization and was recognized for his achievements and contributions as a healthcare leader in PharmaVoice’s “100 of the Most Inspiring People,” Diversity MBA’s “Top 100 Under 50 Diverse Executive Leaders,” and Chicago Business’ “Crain’s 40-under-40.”

Prior to joining Hospira in 2008, Dr. Ramachandra was Vice President and oncology portfolio therapeutic area leader at Merck & Co. (formerly Schering-Plough), and prior to Merck/Schering-Plough he was therapeutic area head for medical oncology at Pfizer (formerly Pharmacia). At these companies, Dr. Ramachandra drove the development, regulatory approval, and market expansion studies for numerous oncology products.

“Sumant brings a broad range of development and regulatory leadership experience, as well as a unique perspective having led both oncology development at large pharmaceutical companies, and the broader range of R&D functions at a large, global specialty pharma company,” said Safi Bahcall, President and CEO, Synta. “Sumant’s experiences with a wide range of drugs, manufacturers, pharma companies, payors, providers, and regulatory agencies will enhance our ability to realize the full potential of our product pipeline to benefit patients.”

“The programs at Synta can change the treatment of many types of cancers,” said Dr. Ramachandra. “In addition, Synta’s culture of innovation, collaboration, and commitment to speed and excellence in execution are exciting and critical to success in our industry. I am very much looking forward to being part of the Synta team and contributing to bringing these new drugs to cancer patients.”

Dr. Ramachandra received a bachelor's degree in biochemistry from Rutgers University, and M.D. and Ph.D. degrees from the University of Medicine and Dentistry-New Jersey Medical School. He conducted his residency at the Harvard-affiliated Massachusetts General Hospital (MGH). Dr. Ramachandra also earned a master's of business administration from the Wharton Business School at the University of Pennsylvania.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 16,643.01 -11.76 -0.07%
S&P 500 1,988.87 +1.21 0.06%
NASDAQ 4,828.3250 +15.6170 0.32%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs